 HOUSTON, June 28, 2021 GLOBE NEWSWIRE -- Bellicum Pharmaceuticals, Inc. NASDAQ:BLCM, a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has entered into a license agreement with the University of North Carolina Lineberger Comprehensive Cancer Center UNC Lineberger and Massachusetts General Hospital Mass General covering certain intellectual property and technology rights regarding the companys CaspaCIDe inducible caspase-9, or iC9 safety switch and related technologies, and the use of rimiducid. CaspaCIDe may facilitate the use of cell therapies where cytokine release syndrome and neurotoxicities have been observed, in the pursuit of novel targets with on-targetoff-tumor safety concerns, and in conjunction with next generation higher potency cell therapy constructs. 